BMRN: Summary for BioMarin Pharmaceutical Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:20am EST - Canadian Markets open in 3 hours and 10 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

BioMarin Pharmaceutical Inc. (BMRN)

On Feb 9: 19.17 USD 0.00 (0.00%)

MORE ON BMRN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

BioMarin Pharmaceutical Inc. (NasdaqNM:BMRN) Delayed quote data

Last Trade:	19.17 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	19.17
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	23.67

Day's Range:	N/A - N/A
52wk Range:	9.93 - 21.50
Volume:	0
Avg Vol (3m):	1,214,370
Market Cap:	1.93B
P/E (ttm):	103.06
EPS (ttm):	0.19
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add BMRN to Portfolio

Download Data

HEADLINES

•	Biotech Stocks: Cell Therapeutics, AstraZeneca lead drug stocks
	at MarketWatch (Tue 1:31pm)

•	BioMarin to Expand, Offers Guidance
	Zacks.com (Tue 11:13am)

•	Biotech Stocks: Drug stocks gain; Cell Therapeutics rebounds
	at MarketWatch (Tue 10:23am)

•	Caterpillar: Analysts' Upgrades, Downgrades
	at TheStreet.com (Tue 9:33am)

•	Biomarin Pharm upgraded by Roth Capital
	Briefing.com (Tue 2:03am)

•	CVS Caremark, Motorola, Hasbro are big movers
	AP (Mon, Feb 8)

•	Biotech Stocks: Drug stocks turn higher; Cell Therapeutics tumbles
	at MarketWatch (Mon, Feb 8)

•	BioMarin shares fall, Brean analyst downgrades
	AP (Mon, Feb 8)

•	Biotech Stocks: BioMarin, Cell Therapeutics lead drug stocks south
	at MarketWatch (Mon, Feb 8)

•	China Biotech Week in Review: New Investments in Life Science
	at Seeking Alpha (Mon, Feb 8)

•	BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement
	EDGAR Online (Fri, Feb 5)

•	BioMarin to buy LEAD for $97M, gives 2010 outlook
	AP (Fri, Feb 5)

More Headlines for BMRN...

ANALYST

EPS Est (next year) (Dec-09) :	-0.04
EPS Est (in 2 years) (Dec-10) :	0.12
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates.

Full Company Profile

Add to Portfolio

Email to a Friend

•